Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?

× No keyword cloud information.

53 in total

1. Treatment of hirsutism with the pure antiandrogen flutamide.

Authors: L Cusan; A Dupont; A Bélanger; R R Tremblay; G Manhes; F Labrie
Journal: J Am Acad Dermatol Date: 1990-09 Impact factor: 11.527

2. The development and evaluation of an ovulation inhibitor (DIAne) containing an antiandrogen.

Authors: U Lachnit-Fixson
Journal: Acta Obstet Gynecol Scand Suppl Date: 1979

3. Cholestatic hepatitis following flutamide.

Authors: A S Rosman; C Frissora-Rodeo; A T Marshall; B P Reiter; F Paronetto
Journal: Dig Dis Sci Date: 1993-09 Impact factor: 3.199

4. Studies on the destruction of adrenal and testicular cytochrome P-450 by spironolactone. Requirement for the 7alpha-thio group and evidence for the loss of the heme and apoproteins of cytochrome P-450.

Authors: R H Menard; T M Guenthner; H Kon; J R Gillette
Journal: J Biol Chem Date: 1979-03-10 Impact factor: 5.157

5. Treatment of female acne vulgaris with a cream containing the antiandrogen canrenone.

Authors: P G Nielsen
Journal: Dermatologica Date: 1983

6. The effect of spironolactone on hirsutism and female androgen metabolism.

Authors: P Dorrington-Ward; A C McCartney; S Holland; J Scully; G Carter; J Alaghband-Zadeh; P Wise
Journal: Clin Endocrinol (Oxf) Date: 1985-08 Impact factor: 3.478

Review 7. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

Authors: A Dunaif
Journal: Endocr Rev Date: 1997-12 Impact factor: 19.871

8. Fatal and nonfatal hepatotoxicity associated with flutamide.

Authors: D K Wysowski; J P Freiman; J B Tourtelot; M L Horton
Journal: Ann Intern Med Date: 1993-06-01 Impact factor: 25.391

9. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.

Authors: E M Velazquez; S Mendoza; T Hamer; F Sosa; C J Glueck
Journal: Metabolism Date: 1994-05 Impact factor: 8.694

10. Evidence for the importance of peripheral tissue events in the development of hirsutism in polycystic ovary syndrome.

Authors: R A Lobo; U Goebelsmann; R Horton
Journal: J Clin Endocrinol Metab Date: 1983-08 Impact factor: 5.958

2 in total

1. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile.

Authors: E Zulian; P Sartorato; S Benedini; G Baro; D Armanini; F Mantero; C Scaroni
Journal: J Endocrinol Invest Date: 2005-01 Impact factor: 4.256

2. Efficacy of Spironolactone in Adult Acne in Polycystic Ovary Syndrome Patients an Original Research.

Authors: Neha Rani; Prashant Kumar; Anup Kumar Mishra; Bala Yadu Vamsi Sankuratri; Sanjana Sethi; Kalyani Gelada; Heena Tiwari
Journal: J Pharm Bioallied Sci Date: 2021-11-10

2 in total